ImmunoGen, Inc. (IMGN) News
Filter IMGN News Items
IMGN News Results
|Loading, please wait...|
IMGN News Highlights
- IMGN's 30 day story count now stands at 19.
- Over the past 25 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- The most mentioned tickers in articles about IMGN are ADC, BEAT and DRUG.
Latest IMGN News From Around the Web
Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., February 25, 2022--ImmunoGen Reports Recent Progress and 2021 Financial Results
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference
WALTHAM, Mass., February 23, 2022--ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.
ImmunoGen Inc (NASDAQ: IMGN ) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY ) to grant exclusive rights to research, develop, and commercialize antibody-drug conjugates (ADCs) directed to targets selected by Lilly based on ImmunoGen''s camptothecin technology. Camptothecins are an important class of anticancer drugs targeting Type I topoisomerase. According to the deal, Lilly … Full story available on Benzinga.com
ImmunoGen Inc. shares jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Camptothecins are a class of cancer drugs. Under the terms of the deal, ImmunoGen will receive $13 million upfront and up to $32.5 million for meeting certain targets. "ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones," the company said in a statement. It will also be eligible for certain tiered royalties as a percentage of worldwide sales. ImmunoGen shares have fallen 47% in the last 12 months, while the S&P 500 has g...
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
WALTHAM, Mass., February 10, 2022--ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
ImmunoGen Inc. (NASDAQ:IMGN) price closed higher on Monday, February 07, jumping 3.95% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy